Monoclonal antibodies (mAbs) are the most prominent
and fastest growing class of therapeutic proteins. With
their excellent biocompatibility and high specificity, mAbs
have been shown to be effective against not only cancer
and inflammatory diseases but also rare diseases such as
Crohn’s disease and paroxysmal nocturnal
haemoglobinuria.1
Recombinant mAbs can be highly
heterogeneous due to various biochemical modifications
such as sialylation, oxidation, deamidation, and
C-terminal lysine truncation.
United States
